Letrozole

Letrozole
Clinical data
Trade names	Femara, others
AHFS/Drugs.com	Monograph
MedlinePlus	a698004
License data	US DailyMed: Letrozole;
Routes of; administration	By mouth
Drug class	Aromatase inhibitor; Antiestrogen
ATC code	L02BG04 (WHO) ;
Legal status
Legal status	CA: Schedule VII; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	99.9%
Protein binding	60%, mainly to albumin
Metabolism	pharmacologically-inactive metabolites Bis(4-cyanophenyl)methanol and 4,4'-dicyanobenzophenone.
Elimination half-life	2 days
Excretion	Kidney
Identifiers
	IUPAC name 4,4'-((1H-1,2,4-triazol-1-yl)methylene)dibenzonitrile;
CAS Number	112809-51-5 ;
PubChem CID	3902;
IUPHAR/BPS	5209;
DrugBank	DB01006 ;
ChemSpider	3765 ;
UNII	7LKK855W8I;
KEGG	D00964 ;
ChEBI	CHEBI:6413 ;
ChEMBL	ChEMBL1444 ;
CompTox Dashboard (EPA)	DTXSID4023202 ;
ECHA InfoCard	100.200.357
Chemical and physical data
Formula	C17H11N5
Molar mass	285.310 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES N#Cc1ccc(cc1)C(c2ccc(C#N)cc2)n3ncnc3;
	InChI InChI=1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H ; Key:HPJKCIUCZWXJDR-UHFFFAOYSA-N ;
	(verify)

Letrozole, sold under the brand name Femara among others, is an aromatase inhibitor medication that is used in the treatment of breast cancer for post-menopausal women.^[1]

It was patented in 1986 and approved for medical use in 1996.^[4] In 2021, it was the 222nd most commonly prescribed medication in the United States, with more than 1 million prescriptions.^[5]^[6] It is on the World Health Organization's List of Essential Medicines.^[7]

^ ^a ^b "Femara- letrozole tablet, film coated". DailyMed. 13 May 2022. Retrieved 28 August 2022.
^ "List of nationally authorised medicinal products : Active substance(s): letrozole : Procedure No. PSUSA/00001842/202110" (PDF). Ema.europa.eu. Retrieved 30 June 2022.
^ ^a ^b ^c "Letrozole". 24 January 2003. Archived from the original on 24 January 2003. Retrieved 30 June 2022.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 516. ISBN 9783527607495.
^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
^ "Letrozole - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

[Femara_FDA_label-1] "Femara- letrozole tablet, film coated". DailyMed. 13 May 2022. Retrieved 28 August 2022.

[2] "List of nationally authorised medicinal products : Active substance(s): letrozole : Procedure No. PSUSA/00001842/202110" (PDF). Ema.europa.eu. Retrieved 30 June 2022.

[Letrozole-3] "Letrozole". 24 January 2003. Archived from the original on 24 January 2003. Retrieved 30 June 2022.

[Fis2006-4] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 516. ISBN 9783527607495.

[5] "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.

[6] "Letrozole - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.

[WHO23rd-7] World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker.

Letrozole

Our website is made possible by displaying online advertisements to our visitors.
Please consider supporting us by disabling your ad blocker.